Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Towa’s Shipment Restriction List Now Expands to 352 Products
Big 3 generic player Towa Pharmaceutical has now seen its list of drugs subject to adjusted shipments grow to 352 products as spillover effects from industry peers continue. The company said on August 11 that it newly added 64 products…
To read the full story
Related Article
- Sawai Now Curbing Shipments for 432 Products
September 24, 2021
- Towa’s Shipment Restriction List Now Expands to 385 Products
September 24, 2021
- Sawai’s Shipment Curbs Now Affect 414 Products
August 20, 2021
- Towa’s Shipment Curbs Now Affect 319 Products, Active Vitamin Analogs Too
July 29, 2021
- Sawai’s Shipment Restrictions Now Reaches 385 Products
July 20, 2021
- Towa’s Shipment Control List Expands to 241 Products; 7 Added
July 13, 2021
- Towa Now Curbs Shipments for 235 Products; 27 Added to Restriction List
July 2, 2021
- Sawai Expands Shipment Adjustments to 369 Products
June 28, 2021
BUSINESS
- Hisamitsu Sets April 17 Shareholders Meeting to Approve Squeeze-Out
March 16, 2026
- AbbVie Japan Files Rinvoq for Vitiligo
March 16, 2026
- SSP Appoints Yoko Motoshima as New President
March 16, 2026
- PMP Returns Slam Drug Makers' Leading Products, Prazaxa Cut 45%: Jiho Poll
March 13, 2026
- Lilly to Invest Additional 20 Billion Yen in Japan's Seishin Plant
March 13, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…